Please login to the form below

Not currently logged in
Email:
Password:

Medius Deal Watch table for February 2015

The top major pharma mergers, acquisitions and collaborations during the month were led by the Pfizer/Hospira and Salix/Valeant deals

Whilst not quite matching January's mega-deal tally February brought home a very respectable score of three deals with values in excess of $1bn. Within the top 20 deals by value for the month the prevailing mood was buy, buy, buy be it wholesale acquisition of companies (6), business units (2) or single assets (2). [Read the month's pharma deal commentary in full.]

Here Medius present a run down of the month's biggest mergers, acquisitions and collaborations from across the sector.  

Licensor Acquired / Licensee Acquirer
Product / Technology
Deal Type
Headline $m
Hospira/ Pfizer
Injectable biosimilar drugs and infusion technologies
Corporate acquisition
17,000
Salix Pharmaceuticals/ Valeant Pharmaceuticals
GI products
Corporate acquisition
14,500
Flexus Biosciences/ BMS
F001287, IDO1 inhibitor + IDO/TDO discovery programme - immuno-oncology
Corporate acquisition
1,250
Voyager Therapeutics/ Sanofi (Genzyme)
Gene therapy - Parkinson's disease, Friedreich's ataxia and Huntington's disease
Collaboration - discover, develop, commercialise
845
Famy Care/ Mylan
Female healthcare businesse
Acquisition - business units
800
*Actavis/ AstraZeneca
Respiratory medicines
Acquisition - business unit
700
NGM Biopharmaceuticals/ Merck & Co
NP201 + other preclinical candidates - diabetes, obesity, non-alcoholic steatohepatitis (NASH)
Collaboration - discover, develop, commercialise
450
Heptares Therapeutics/ Sosei Group 
Novel G protein-coupled receptor targeted drug candidates - Alzheimer's disease, metabolic disease, schizophrenia, migraine etc
Corporate acquisition
400
Dendreon/ Valeant Pharmaceuticals
PROVENGE® (sipuleucel-T) and other assets - prostate cancer
Corporate acquisition
400
Shanxi Powerdone/ Harbin Gloria Pharma
Chemical drug and compound preparation manufacturing
Majority acquisition
380
Pfenex/ Hospira
PF582 -  LUCENTIS® biosimilar candidate - wet age-related macular degeneration, diabetic macular oedema
Collaboration - develop and commercialise
342
Rigel Pharmaceuticals/ BMS
Small molecule TGF beta receptor kinase inhibitors - immuno-oncology
Collaboration - discover, develop, commercialise
339
Theravance/ Mylan
TD-4208- a novel once-daily nebulised long-acting muscarinic antagonist (LAMA) - COPD
Collaboration - develop and commercialise
265
Meritage Pharma/ Shire
Phase 3-ready oral budesonide suspension (OBS) - eosinophilic esophagitis (EoE)
Corporate acquisition
245††
Vernalis/  Not disclosed
Adenosine receptor antagonist programme, including the lead drug candidate, V81444
Licence
201
GlycoVaxyn/ GSK
Conjugation platform plus early stage vaccines against bacterial infections such as pneumonia, Pseudomonas, S. aureus and Shigellosis
Corporate acquisition
190
**Amarin/ Eddingpharm
VASCEPA® (icosapent ethyl) - triglyceride level reduction
Collaboration - develop and commercialise
169
Orca Pharmaceuticals/ AstraZeneca
Retinoic acid-related orphan nuclear receptor gamma (RORγ) inhibitors - autoimmune diseases
Collaboration - discover, develop, commercialise
122.5
***Neutec/ Takeda
Portfolio of 13 drugs - GI, respiratory, metabolic and musculoskeletal
Asset acquisition - products
121
†Eagle Pharmaceuticals/ Teva
EP-3102 - bendamustine hydrochloride rapid infusion product - CLL, indolent B-cell NHL
Licence - distribute and promote
120

All deals global unless otherwise stated:
*  US and Canada
** China, Hong  Kong, Macao Special Administrative Regions, Taiwan
*** Turkey
†  US
††  Financial details source - Viropharma's 2013 Consolidated Financial Statement
 
Abbreviations:
IDO, Indoleamine-2, 3-dioxygenase;  TDO, Tryptophan-2,3- dioxygenase
COPD, chronic obstructive pulmonary disease
CLL, chronic lymphocytic leukaemia;  NHL, indolent non-Hodgkin lymphoma

The Deal Watch table is compiled by Medius Associates

27th April 2015

From: Sales

Share

Tags


Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Infographics